Clinical trial · Interventional
Salvage Prostatectomy After Radiotherapy
Salvage Prostatectomy After Radiotherapy: Whole-Mount Histopathological Validation for Tumor-Targeted Salvage HDR Brachytherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the location of the cancer found in the prostate gland after it is removed to the location that was predicted on the MRI scan during biopsy. In this way, we can better determine if the Magnetic Resonance Imaging (MRI) was accurate, and if the MRI could be safely used to guide other types of treatments such as brachytherapy. We also plan to carefully measure how frequently surgery is able to completely remove the cancer, as well as the side effects and effectiveness of surgery after radiotherapy. The study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to this trial (UHN 05-0641-C).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| whole-mount sectioning of the prostate | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- prostatectomy after radiotherapy
- interventionNames
- Procedure: whole-mount sectioning of the prostate
Primary outcomes (1)
- measure
- To Validate virtual dosimetry plans for tumor-targeted salvage (High-Dose-Rate) HDR brachytherapy against co-registered whole-mount prostatectomy specimens.
- timeFrame
- Patients will have follow-up assessments at 1,3 and 6 months and 1,2,3 and 5 years after surgery.
Secondary outcomes (1)
- measure
- Preliminary evaluation of surgical margin status, toxicity and QOL, and biochemical control after salvage RP.
- timeFrame
- Patients will have follow-up assessments at 1,3 and 6 months and 1,2,3 and 5 years after surgery.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prior enrollment of UHN 05-0641-C * Histological evidence of cancer on MRI-guided prostate biopsy * PSA doubling time \> 6 months * ECOG 0 or 1 * All patients must give written informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed Exclusion Criteria: * Contraindications to salvage prostatectomy * Previous rectal surgery for IBD or cancer such that an ileo-anal anastomosis is present. * Radiological evidence of regional or distant metastases
References
Publications (0)
Data not yet available